Showing results (201-210 of 4,635) with videos related to

Sort By:
Pageof 464
Anti-Cancer Drugs|October 21, 2004
Chemoradiation with gemcitabine for cervical cancer in patients with renal failureLucely Cetina, Lesbia Rivera, Myrna Candelaria, et al.
Anti-Cancer Drugs|March 5, 2005
Hyaluronic acid butyric esters in cancer therapyAnnalisa Speranza, Cinzia Pellizzaro, Danila Coradini
Anti-Cancer Drugs|March 5, 2005
High cytotoxic sensitivity of the human small cell lung doxorubicin-resistant carcinoma (GLC4/ADR) cell line to prodigiosin through apoptosis activationEsther Llagostera, Vanessa Soto-Cerrato, Ricky Joshi, et al.
Anti-Cancer Drugs|March 5, 2005
In vitro assessment of cytotoxic agent combinations for hormone-refractory prostate cancer treatmentAurélie Cabrespine, Jacques-Olivier Bay, Chantal Barthomeuf, et al.
Anti-Cancer Drugs|March 5, 2005
Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: results of a phase II trialSenta Ulrike Gnad-Vogt, Ralf-Dieter Hofheinz, Susanne Saussele, et al.
Anti-Cancer Drugs|May 29, 2004
Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-I: hepatic arterial embolization and embolization-based therapies in unresectable hepatocellular carcinomaDiane L Reidy, Jonathan D Schwartz
Anti-Cancer Drugs|May 29, 2004
Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategyCeleste Lindley, Thomas Shea, Jeannine McCune, et al.
Anti-Cancer Drugs|May 29, 2004
Biweekly docetaxel as second-line chemotherapy of patients with advanced non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 006-00)Sergio Vázquez, Carlos Grande, Margarita Amenedo, et al.
Anti-Cancer Drugs|May 29, 2004
Preliminary study on pharmacokinetics of dacarbazine and fotemustine in glioblastoma multiforme patients does not indicate gender-specific differencesBarbara Fazeny-Dörner, Robert M Mader, Maria Piribauer, et al.
Anti-Cancer Drugs|April 20, 2004
XR5967, a novel modulator of plasminogen activator inhibitor-1 activity, suppresses tumor cell invasion and angiogenesis in vitroTeresa D Brooks, Shouming W Wang, Nils Brünner, et al.
Pageof 464